Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve Prior Intimation of Board Meeting ....

APTUS PHARMA LIMITED To, Date: 12/08/2026 Corporate Rela(cid:415)on Departments The BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 SECURITY CODE: 544529 SCRIPT SYMBOL: APPL ISIN: INE15XJ01010 Dear Sir / Madam, Sub: Prior Intimation of Board Meeting to be held on Monday, August 17, 2026. Ref: Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) and intimation regarding closure of trading window. Pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR Regulations"), we hereby give prior intimation that a Meeting of the Board of Directors of Aptus Pharma Limited (hereinafter referred to as "the Company") is scheduled to be held on Monday, August 17, 2026 at 4:00 p.m. at the Head office of the Company situated at RK Trade Tower, Wing A, Office 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India, 360006, inter alia, to consider and deliberate upon the following proposed agenda item: 1. To take on record the valuation report for price of Preferential issue. 2. To determine an issue price on the basis of the valuation report to be obtained from the Registered Valuer for Issue of 16,10,100 equity shares of the Company, on a preferential basis having regard to the relevant date of August 14, 2026. 3. To take on record the PCS certificate confirming compliance with all ICDR and companies act, 2013 provisions for the proposed preferential issue. 4. To take on record Auditor certificate for Preferential issue. 5. Convening of the 16th Annual General Meeting of the Company on Monday, September 14, 2026, through Video Conferencing/Other Audio-Visual Means, and approval of the Notice of the Annual General Meeting, including the explanatory statement annexed thereto; and 6. To transact any other business with the permission of the Chair. Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logis(cid:415)c Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM APTUS PHARMA LIMITED Further to the above, and in terms of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("SEBI PIT Regulations"), as amended, read with the Company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives framed thereunder ("Code of Conduct"), the Trading Window for dealing in the securities of the Company stands closed for all Designated Persons and their Immediate Relatives with effect from Wednesday, 12th August, 2026 (6:00 p.m.), i.e., from the date and time of this intimation, and shall remain closed until the expiry of 48 (forty-eight) hours after the outcome of the aforesaid Board Meeting is disseminated to the Stock Exchange(s) in terms of Regulation 30 of the SEBI LODR Regulations. All Designated Persons of the Company and their Immediate Relatives are hereby informed and directed not to trade in the securities of the Company during the aforesaid period of closure of the trading window. Kindly take the above on record. Thanking You, Yours faithfully, For Aptus Pharma Limited Tejash Maheshchandra Hathi Managing Director DIN: 03151221 Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logis(cid:415)c Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM